AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11890163 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat combined with an energy and fat restricted diet
Number of subjects: 12
Study 11890163 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with an energy and fat restricted diet
Number of subjects: 12
Study 9861119 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 10 ml h‐1 (group N)
Number of subjects: 50
Study 9861119 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 50
Study 7714107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 10(6) IU iv IFN‐alpha 2
Number of subjects: 8
Study 7714107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg Dex (1 mg at midnight the previous night and 0.5 mg at 0700 h on the day of the test) + 3 x 10(6) IU iv IFN‐alpha 2
Number of subjects: 8
Study 7714107 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg Dex (1 mg at midnight the previous night and 0.5 mg at 0700 h on the day of the test) + 2 mL iv saline
Number of subjects: 8
Study 7714107 — intervention group
Group type: COMPARATOR
Intervention: 2 mL iv saline
Number of subjects: 8
Study 2668037 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-operative blood transfusions
Number of subjects: 212
Study 2668037 — intervention group
Group type: COMPARATOR
Intervention: No peri-operative blood transfusions
Number of subjects: 212
Study 1259521 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazines (twice daily schedule)
Number of subjects: 27
Study 1259521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 27
Study 1259521 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenothiazines (after cessation)
Number of subjects: 27
Study 29229058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 122
Study 29229058 — intervention group
Group type: COMPARATOR
Intervention: Qigong therapy
Number of subjects: 122
Study 29229058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 122
Study 26205524 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrodesis plus Total Contact Casting (TCC)
Number of subjects: 21
Study 26205524 — intervention group
Group type: COMPARATOR
Intervention: Total Contact Casting (TCC)
Number of subjects: 21
Study 23415543 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (L-DOPA) treatment
Number of subjects: 35
Study 23415543 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 35
Study 21812263 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus Injection (2 mL/kg)
Number of subjects: 40
Study 21812263 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40
Study 19442784 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (DOX; 20 mg) twice a day
Number of subjects: 0
Study 19442784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 19442784 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing subcutaneous implant (LNG SI)
Number of subjects: 0
Study 16928840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl vinyl chloride vapocoolant spray
Number of subjects: 127
Study 16928840 — intervention group
Group type: COMPARATOR
Intervention: Isopropyl alcohol spray (placebo)
Number of subjects: 127
Study 16928840 — intervention group
Group type: COMPARATOR
Intervention: No spray (control)
Number of subjects: 127
Study 15468351 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate
Number of subjects: 41
Study 11343405 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged in interactions and imagined others; memory test repeated 1 week later.
Number of subjects: 0
Study 11343405 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities where participant was the agent of action.
Number of subjects: 0
Study 11343405 — intervention group
Group type: EXPERIMENTAL
Intervention: Object use during the activity.
Number of subjects: 0
Study 11343405 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity among actions.
Number of subjects: 0
Study 9460299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 9460299 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8186064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (200 micrograms three times daily)
Number of subjects: 56
Study 8186064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8186064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide
Number of subjects: 56
Study 3792086 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (100, 200, 600, or 1,200 micrograms)
Number of subjects: 11
Study 3792086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30462938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (1×10^10 CFU twice daily for 5 days)
Number of subjects: 971
Study 30462938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 971
Study 30462938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 971
Study 27009465 — intervention group
Group type: EXPERIMENTAL
Intervention: DEAL Project (automated Web‐based self‐help intervention)
Number of subjects: 104
Study 27009465 — intervention group
Group type: COMPARATOR
Intervention: HealthWatch (Web‐based attention-control condition)
Number of subjects: 104
Study 25565480 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive rehabilitation and right hemifield eye-patching
Number of subjects: 12
Study 25565480 — intervention group
Group type: COMPARATOR
Intervention: Computer-based cognitive rehabilitation alone
Number of subjects: 12
Study 23297772 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMX, 500 mg) + Metronidazole (MET, 250 mg), TID for 10 days
Number of subjects: 35
Study 23297772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 20492045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese food therapy (specific dietary instructions, management of antihypertensive medication, brief health education)
Number of subjects: 85
Study 20492045 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese food therapy
Number of subjects: 85
Study 20492045 — intervention group
Group type: COMPARATOR
Intervention: Routine support (brief health education)
Number of subjects: 85
Study 18672776 — intervention group
Group type: COMPARATOR
Intervention: Valaciclovir alone (Group B)
Number of subjects: 97
Study 18672776 — intervention group
Group type: EXPERIMENTAL
Intervention: QLM plus valaciclovir (Group C)
Number of subjects: 97
Study 15905632 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at three different stimulation intensities
Number of subjects: 10
Study 12580992 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplements (10 mg of Natural Source Odourless Garlic)
Number of subjects: 10
Study 10867376 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen specific immunotherapy with birch and/or timothy pollen allergen extract
Number of subjects: 210
Study 10867376 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only pharmacotherapy
Number of subjects: 210
Study 10867376 — intervention group
Group type: EXPERIMENTAL
Intervention: D. Pteronyssinus immunotherapy
Number of subjects: 210
Study 10867376 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving medication only
Number of subjects: 210
Study 8889739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 60% VO2max
Number of subjects: 5
Study 8889739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 75% VO2max
Number of subjects: 5
Study 8889739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 30% VO2max
Number of subjects: 5
Study 8889739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 45% VO2max
Number of subjects: 5
Study 8889739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 30% and 45% VO2max
Number of subjects: 5
Study 8889739 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at lower intensities (30% and 45% VO2max)
Number of subjects: 5
Study 2070239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral paramedian incision with layered closure
Number of subjects: 349
Study 2070239 — intervention group
Group type: COMPARATOR
Intervention: Midline incision with mass closure
Number of subjects: 349
Study 2070239 — intervention group
Group type: COMPARATOR
Intervention: Midline incision with layered closure
Number of subjects: 349
Study 6685418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment for mastopathy
Number of subjects: 0
Study 6685418 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hormonal treatment for mastopathy
Number of subjects: 0
Study 6685418 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment of mastopathy
Number of subjects: 0
Study 31372649 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral letters
Number of subjects: 100
Study 31372649 — intervention group
Group type: EXPERIMENTAL
Intervention: Response letters
Number of subjects: 100
Study 30955869 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (after conversion from cyclosporine)
Number of subjects: 89
Study 30955869 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitope load greater than 27
Number of subjects: 89
Study 30955869 — intervention group
Group type: COMPARATOR
Intervention: HLA mismatches
Number of subjects: 89
Study 30955869 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitope load threshold of 27
Number of subjects: 89
Study 26522915 — intervention group
Group type: EXPERIMENTAL
Intervention: SnFl-Zn mouthwash
Number of subjects: 20
Study 26522915 — intervention group
Group type: EXPERIMENTAL
Intervention: alcohol-free EO mouthwash
Number of subjects: 20
Study 26522915 — intervention group
Group type: COMPARATOR
Intervention: CHX mouthwash
Number of subjects: 20
Study 26768126 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) TBE vaccination
Number of subjects: 116
Study 26768126 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) TBE vaccination
Number of subjects: 116
Study 25151646 — intervention group
Group type: EXPERIMENTAL
Intervention: HeadStrong
Number of subjects: 380
Study 25151646 — intervention group
Group type: COMPARATOR
Intervention: Personal Development, Health and Physical Education (PDHPE)
Number of subjects: 380
Study 22483860 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factor Plasma (PRGF)
Number of subjects: 176
Study 22483860 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRGF treatment)
Number of subjects: 176
Study 20618356 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.1 nmol kg⁻¹ min⁻¹)
Number of subjects: 8
Study 20618356 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 17627239 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy
Number of subjects: 122
Study 17627239 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy (after excluding reoperated/converted donors)
Number of subjects: 122
Study 17627239 — intervention group
Group type: COMPARATOR
Intervention: Open nephrectomy
Number of subjects: 122
Study 15787942 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 11
Study 15787942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 15922478 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg emtricitabine once daily
Number of subjects: 0
Study 15922478 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg emtricitabine once daily
Number of subjects: 0
Study 15922478 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine once daily
Number of subjects: 0
Study 15922478 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine open-label after 48 weeks
Number of subjects: 0
Study 10370678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with doxorubicin 50 mg/m2
Number of subjects: 72
Study 10370678 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy with doxorubicin 50 mg/m2
Number of subjects: 72
Study 8677192 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) secretion in patients with ARSD under water immersion (IW)
Number of subjects: 30
Study 8677192 — intervention group
Group type: EXPERIMENTAL
Intervention: Water, Na, Ca, Mg, and oxalic acid excretion in patients with ARSD under water immersion (IW)
Number of subjects: 30
Study 8677192 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum ANP levels and urinary excretion of Na, Ca, and Mg in patients with ARSD
Number of subjects: 30
Study 8677192 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between serum ANP levels and urinary excretion of oxalic acid in patients with ARSD during water immersion (IW)
Number of subjects: 30
Study 1854252 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 alone
Number of subjects: 43
Study 1854252 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus lymphokine-activated killer cells
Number of subjects: 43
Study 1854252 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone and IL-2 plus lymphokine-activated killer cells
Number of subjects: 43
Study 6626018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% aqueous suspension
Number of subjects: 0
Study 6626018 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% oil suspension
Number of subjects: 0
Study 6626018 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin
Number of subjects: 0
Study 31477160 — intervention group
Group type: EXPERIMENTAL
Intervention: TRIUMPH intervention (standardised LUTS advice booklet delivered by nurses/healthcare assistants with follow-up contacts over 12 weeks)
Number of subjects: 30
Study 31477160 — intervention group
Group type: COMPARATOR
Intervention: Usual care pathway
Number of subjects: 30
Study 28482106 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Physical Activity (PA)
Number of subjects: 1635
Study 28482106 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 1635
Study 26209003 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics (40 mg furosemide equivalents)
Number of subjects: 475
Study 25194668 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-containing deodorant and soap
Number of subjects: 333
Study 25194668 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aluminum containing deodorant and soap
Number of subjects: 333
Study 25194668 — intervention group
Group type: COMPARATOR
Intervention: Soap (control)
Number of subjects: 333
Study 22421631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (10-40 mg/day, titrated based on BP response)
Number of subjects: 207
Study 22421631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 22421631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 207
Study 20600557 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 ppm NaF
Number of subjects: 50
Study 20600557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm NaF
Number of subjects: 50
Study 20600557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm NaF
Number of subjects: 50
Study 20600557 — intervention group
Group type: EXPERIMENTAL
Intervention: 19000 ppm NaF
Number of subjects: 50
Study 20600557 — intervention group
Group type: COMPARATOR
Intervention: Distilled water control
Number of subjects: 50
Study 17905046 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of burn victims
Number of subjects: 273
Study 15629969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 44
Study 15629969 — intervention group
Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 44
Study 12242072 — intervention group
Group type: EXPERIMENTAL
Intervention: Group AGG (serial external electrical cardioversion)
Number of subjects: 90
Study 12242072 — intervention group
Group type: COMPARATOR
Intervention: Group CTL (non-treatment of atrial fibrillation relapse)
Number of subjects: 90
Study 10354031 — intervention group
Group type: EXPERIMENTAL
Intervention: Humoristic leaflet (H‐leaflet)
Number of subjects: 300
Study 10354031 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarmist leaflet (A‐leaflet)
Number of subjects: 300
Study 10354031 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral information leaflet (N‐leaflet)
Number of subjects: 300
Study 10354031 — intervention group
Group type: COMPARATOR
Intervention: No leaflet (Control)
Number of subjects: 300
Study 7486182 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 30
Study 7486182 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 30
Study 7486182 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 30527630 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal cannula placement (within 1cm of the right hepatic vein orifice)
Number of subjects: 32
Study 30527630 — intervention group
Group type: COMPARATOR
Intervention: Distal cannula placement (within 1cm of the right hepatic vein orifice)
Number of subjects: 32
Study 28704126 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) treatment
Number of subjects: 1196
Study 27228433 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher visit-to-visit systolic blood pressure variability (SBPV)
Number of subjects: 4745
Study 27228433 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit diastolic blood pressure variability (DBPV)
Number of subjects: 4745
Study 24533697 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600/900 μg bid
Number of subjects: 162
Study 22145743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention
Number of subjects: 113
Study 22145743 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene educational programs
Number of subjects: 113
Study 22145743 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 113
Study 22145743 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (female)
Number of subjects: 113
Study 22145743 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of oral hygiene behaviour at 3 months
Number of subjects: 113
Study 21105556 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG with pre-selected abnormalities
Number of subjects: 35
Study 21105556 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray with cardio-thoracic ratio > 0.5
Number of subjects: 35
Study 21105556 — intervention group
Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 35
Study 21105556 — intervention group
Group type: COMPARATOR
Intervention: ECG
Number of subjects: 35
Study 21105556 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 35
Study 17551129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d of folic acid
Number of subjects: 1021
Study 17551129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study 15198752 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy intervention program (6 sessions between weeks 2 and 6 after birth)
Number of subjects: 199
Study 15198752 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 199
Study 15198752 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 199
Study 11480595 — intervention group
Group type: EXPERIMENTAL
Intervention: New Charnley instrumentation
Number of subjects: 123
Study 11480595 — intervention group
Group type: COMPARATOR
Intervention: Original method
Number of subjects: 123
Study 9494705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion methodology
Number of subjects: 0
Study 9494705 — intervention group
Group type: COMPARATOR
Intervention: Lithium treatment
Number of subjects: 0
Study 8974346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-muscular thiamin
Number of subjects: 0
Study 8974346 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3288460 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine daily intravenously for a mean of 3.9 days
Number of subjects: 400
Study 3288460 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ranitidine daily intravenously for a mean of 3.9 days
Number of subjects: 400
Study 3288460 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ranitidine
Number of subjects: 400
Study 3288460 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine
Number of subjects: 400
Study 30683061 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract (400 mg twice a day for 8 weeks)
Number of subjects: 42
Study 30683061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 28424871 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab
Number of subjects: 170
Study 28424871 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 170
Study 26563012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg), administered once daily for 2 days and tapered down, completed on day 10
Number of subjects: 65
Study 26563012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 26563012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (1 mg/kg)
Number of subjects: 65
Study 23308174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (100 ug/kg single dose)
Number of subjects: 61
Study 23308174 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 ug/kg/day for 9 doses)
Number of subjects: 61
Study 23308174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 61
Study 21657939 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture reinforcement
Number of subjects: 20
Study 21657939 — intervention group
Group type: EXPERIMENTAL
Intervention: Seamguard reinforcement
Number of subjects: 20
Study 21657939 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue (excluded from analysis)
Number of subjects: 20
Study 18834464 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 66